JASON R GOTLIB

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy
    Jason Gotlib
    Stanford Cancer Center, 875 Blake Wilbur Drive, Room 2327B, Stanford, CA 94305 5821, USA
    Best Pract Res Clin Haematol 19:535-69. 2006
  2. doi request reprint World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management
    Jason Gotlib
    Division of Hematology, Stanford University Medical Center, Palo Alto, CA, USA
    Am J Hematol 87:903-14. 2012
  3. ncbi request reprint The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management
    Jason Gotlib
    Division of Hematology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA 94305 5821, USA
    Blood 103:2879-91. 2004
  4. doi request reprint World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management
    Jason Gotlib
    Division of Hematology, Department of Medicine, Stanford University School of Medicine Stanford Cancer Center, Stanford, California 94305 5821, USA
    Am J Hematol 86:677-88. 2011
  5. doi request reprint Eosinophilic myeloid disorders: new classification and novel therapeutic strategies
    Jason Gotlib
    Stanford University School of Medicine, Stanford Cancer Center, Stanford, California, USA
    Curr Opin Hematol 17:117-24. 2010
  6. doi request reprint A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes
    Jason Gotlib
    Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305 5821, USA
    Am J Hematol 84:15-20. 2009
  7. doi request reprint Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias
    J Gotlib
    Department of Medicine, Division of Hematology, Stanford Cancer Center, Stanford, CA 94305 5821, USA
    Leukemia 22:1999-2010. 2008
  8. ncbi request reprint KIT mutations in mastocytosis and their potential as therapeutic targets
    Jason Gotlib
    Stanford Cancer Center, Stanford University School of Medicine, 875 Blake Wilbur Drive, Room 2327B, Stanford, CA 94305 5821, USA
    Immunol Allergy Clin North Am 26:575-92. 2006
  9. ncbi request reprint Molecular classification and pathogenesis of eosinophilic disorders: 2005 update
    Jason Gotlib
    Stanford Cancer Center, 875 Blake Wilbur Drive, Rm 2327B, Stanford, CA 94305 5821, USA
    Acta Haematol 114:7-25. 2005
  10. ncbi request reprint Farnesyltransferase inhibitor therapy in acute myelogenous leukemia
    Jason Gotlib
    Division of Hematology, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Curr Hematol Rep 4:77-84. 2005

Research Grants

Detail Information

Publications16

  1. ncbi request reprint Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy
    Jason Gotlib
    Stanford Cancer Center, 875 Blake Wilbur Drive, Room 2327B, Stanford, CA 94305 5821, USA
    Best Pract Res Clin Haematol 19:535-69. 2006
    ....
  2. doi request reprint World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management
    Jason Gotlib
    Division of Hematology, Stanford University Medical Center, Palo Alto, CA, USA
    Am J Hematol 87:903-14. 2012
    ..The eosinophilias encompass a broad range of nonhematologic (secondary or reactive) and hematologic (primary, clonal) disorders with potential for end-organ damage...
  3. ncbi request reprint The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management
    Jason Gotlib
    Division of Hematology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA 94305 5821, USA
    Blood 103:2879-91. 2004
    ..This review examines the current state of knowledge of HES and CEL and the implications of the FIP1L1-PDGFRA discovery on their diagnosis, classification, and management...
  4. doi request reprint World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management
    Jason Gotlib
    Division of Hematology, Department of Medicine, Stanford University School of Medicine Stanford Cancer Center, Stanford, California 94305 5821, USA
    Am J Hematol 86:677-88. 2011
    ..The eosinophilias encompass a broad range of non-hematologic (secondary or reactive) and hematologic (primary, clonal) disorders with potential for end-organ damage...
  5. doi request reprint Eosinophilic myeloid disorders: new classification and novel therapeutic strategies
    Jason Gotlib
    Stanford University School of Medicine, Stanford Cancer Center, Stanford, California, USA
    Curr Opin Hematol 17:117-24. 2010
    ..The aim of this brief review is to evaluate recent developments in the classification and treatment of eosinophilic myeloid disorders in the context of reactive, lymphocyte-variant, and idiopathic eosinophilias...
  6. doi request reprint A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes
    Jason Gotlib
    Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305 5821, USA
    Am J Hematol 84:15-20. 2009
    ..Our data indicate that weekly weight-based dosing of DA, with the addition of G-CSF in selected individuals, can be an effective erythropoietic option in a high proportion of lower-risk MDS patients...
  7. doi request reprint Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias
    J Gotlib
    Department of Medicine, Division of Hematology, Stanford Cancer Center, Stanford, CA 94305 5821, USA
    Leukemia 22:1999-2010. 2008
    ....
  8. ncbi request reprint KIT mutations in mastocytosis and their potential as therapeutic targets
    Jason Gotlib
    Stanford Cancer Center, Stanford University School of Medicine, 875 Blake Wilbur Drive, Room 2327B, Stanford, CA 94305 5821, USA
    Immunol Allergy Clin North Am 26:575-92. 2006
    ..In addition, the generation of murine models that recapitulate human mastocytosis should accelerate preclinical testing of novel agents...
  9. ncbi request reprint Molecular classification and pathogenesis of eosinophilic disorders: 2005 update
    Jason Gotlib
    Stanford Cancer Center, 875 Blake Wilbur Drive, Rm 2327B, Stanford, CA 94305 5821, USA
    Acta Haematol 114:7-25. 2005
    ..Success in establishing the molecular basis of a group of once seemingly heterogeneous diseases has now the laid the foundation for establishing a semi-molecular classification scheme of eosinophilic disorders...
  10. ncbi request reprint Farnesyltransferase inhibitor therapy in acute myelogenous leukemia
    Jason Gotlib
    Division of Hematology, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Curr Hematol Rep 4:77-84. 2005
    ..Preclinical concepts related to the development of FTIs, the rationale for their use in AML, and efficacy and safety results from recent clinical trials are evaluated in this paper...
  11. pmc Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
    Jason Gotlib
    Department of Medicine, Division of Hematology, Stanford University, Stanford Cancer Center, 875 Blake Wilbur Dr, Rm 2327B, Stanford, CA 94305 5821, USA
    Blood 106:2865-70. 2005
    ..This case indicates that KIT tyrosine kinase inhibition is a feasible approach in SM, but single-agent clinical efficacy may be limited by clonal evolution in the advanced leukemic phase of this disease...
  12. pmc Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
    MICHAELA LIEDTKE
    Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Haematologica 97:30-7. 2012
    ....
  13. pmc Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
    Daniel A Pollyea
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Haematologica 98:591-6. 2013
    ..In conclusion, a sequential combination of azacitidine plus lenalidomide has clinical activity in older patients with acute myeloid leukemia, and further studies of this combination are underway...
  14. doi request reprint DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups
    Robert S Ohgami
    Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
    Br J Haematol 159:182-90. 2012
    ....
  15. pmc Treatment advances have not improved the early death rate in acute promyelocytic leukemia
    James Scott McClellan
    Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305 5821, USA
    Haematologica 97:133-6. 2012
    ..Our findings show that early death is now the greatest contributor to treatment failure in this otherwise highly curable form of leukemia...
  16. doi request reprint Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 29:789-96. 2011
    ..Patients frequently harbor JAK-STAT activating mutations that are sensitive to TG101348, a selective small-molecule Janus kinase 2 (JAK2) inhibitor...

Research Grants1

  1. FTI Biology & Treatment of Myeloproliferative Disorders
    Jason Gotlib; Fiscal Year: 2005
    ..If clinically efficacious, further studies of R115777 in MPDs will be warranted...